We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
101
PUT
DELISTED
Dermira, Inc.
DERM
$94K 0.14%
+10,000
New +$262K
CYTK icon
102
CALL
Cytokinetics
CYTK
$10.9B
$93K 0.14%
+31,100
New +$425K
GILD icon
103
CALL
Gilead Sciences
GILD
$167B
$92K 0.14%
+60,000
New +$4.59M
IONS icon
104
CALL
Ionis Pharmaceuticals
IONS
$8.99B
$90K 0.14%
+84,000
New +$4.4M
LRMR icon
105
Larimar Therapeutics
LRMR
$384M
$90K 0.14%
2,138
-2,951
-58% -$123K
SVVC
106
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
$88K 0.13%
11,000
-9,000
-45% -$70.5K
IBB icon
107
PUT
iShares Biotechnology ETF
IBB
$9.23B
$86K 0.13%
88,500
+19,500
+28% +$2.08M
AIMT
108
CALL
DELISTED
Aimmune Therapeutics
AIMT
$84K 0.13%
+70,000
New +$1.51M
ZYNE
109
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$82K 0.12%
45,000
+42,000
+1,400% +$444K
TTPH
110
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$82K 0.12%
+600
New +$80.3K
HAIN icon
111
Hain Celestial
HAIN
$50.6M
$74K 0.11%
1,800
-8,200
-82% -$339K
HSY icon
112
CALL
Hershey
HSY
$34.8B
$74K 0.11%
73,000
+16,000
+28% +$1.7M
PRTK
113
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$69K 0.1%
+2,748
New +$64K
CL icon
114
PUT
Colgate-Palmolive
CL
$74.4B
$67K 0.1%
28,500
-5,000
-15% -$360K
CL icon
115
Colgate-Palmolive
CL
$74.4B
$66K 0.1%
900
-12,847
-93% -$926K
MON
116
CALL
DELISTED
Monsanto Co
MON
$65K 0.1%
21,400
-3,000
-12% -$353K
KSS icon
117
CALL
Kohl's
KSS
$1.96B
$60K 0.09%
+17,500
New +$717K
LJPC
118
PUT
DELISTED
La Jolla Pharmaceutical Company
LJPC
$55K 0.08%
+38,000
New +$1.22M
ABBV icon
119
CALL
AbbVie
ABBV
$450B
$53K 0.08%
30,000
+20,000
+200% +$1.52M
SRPT icon
120
PUT
Sarepta Therapeutics
SRPT
$1.82B
$51K 0.08%
55,500
+35,500
+178% +$1.42M
FCSC
121
PUT
DELISTED
Fibrocell Science Inc.
FCSC
$51K 0.08%
+24,120
New +$390K
ZSAN
122
DELISTED
Zosano Pharma Corporation
ZSAN
$49K 0.07%
86
– –
BMY icon
123
PUT
Bristol-Myers Squibb
BMY
$124B
$48K 0.07%
60,100
+30,300
+102% +$1.77M
IONS icon
124
PUT
Ionis Pharmaceuticals
IONS
$8.99B
$48K 0.07%
+20,300
New +$1.06M
ONCE
125
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$48K 0.07%
+8,900
New +$676K
3 4
5
6 7

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.